B
B

BayerAG


News

European stocks log best session in 6 weeks as cyclicals roar back

* Swedish Match up on $16 bln bid from Philip Morris * ECB's Lagarde cements rate hike expectations * Bayer drops on setback in Roundup dispute * U.S. consumer price gains slow but inflation still hot By Sruthi Shankar and Shreyashi Sanyal May 11 (Reuters) - European stocks locked in gains for a second straight session on Wednesday as strong earnin
A
B
C
T
S
E
F
U
G

Bayer says Ukraine farmers progress with planting despite war

FRANKFURT, May 10 (Reuters) - Farmers in Ukraine have made better-than-expected progress preparing their fields so far despite Russia's attack on the country, the world's largest supplier of seeds and crop chemicals, Bayer BAYGn.DE , said on Tuesday. "Not only us but all companies that operate in the (agricultural) inputs area have gone out of thei
B
B
C

African Union crafts guidelines for GM crops, activists raise alarm

* New push for harmonisation of GMO regulations in Africa * Only seven African countries have commercial GM output * Backers of GM crops says they will improve food security * Critics raise safety concerns, say poor farmers will suffer By Wendell Roelf CAPE TOWN, Aug 31 (Reuters) - The African Union is developing guidelines for the use of genetical
B

European shares notch fourth straight record high on earnings strength

* Novo Nordisk among top boosts * Zalando, Adidas knock down retail sector * Mining stocks down on Chinese demand fears * BoE outlines plans for reducing stimulus By Sruthi Shankar and Ambar Warrick Aug 5 (Reuters) - European stocks ended at record highs on Thursday, as strong results from Novo Nordisk and Siemens helped outweigh weak mining stocks
A
B
B
E
S
Z
G
E
F
U

CureVac 19 vaccine records only 48% efficacy in final trial readout

By Ludwig Burger June 30 (Reuters) - CureVac 5CV.DE said its COVID-19 vaccine was 48% effective in the final analysis of its pivotal mass trial, only marginally better than the 47% reported after an initial read-out two weeks ago. The German biotech firm said that efficacy, measured by preventing symptomatic disease, was slightly better at 53% when
B
G
N
P

CureVac may let contractors make rival vaccines if own shot fails -CEO

By Tilman Blasshofer and Ludwig Burger FRANKFURT, June 17 (Reuters) - German biotech firm CureVac 5CV.DE could allow its network of manufacturing partners to be repurposed to make vaccines developed by other companies should its own experimental shot fail, its chief executive told Reuters on Thursday. The German company saw billions of euros wiped
B
G
N
P
W

Swiss reject law to help country meet Paris carbon emissions goal

* Swiss voted on five issues in national referendums * New CO2 Law to help cut carbon emissions narrowly rejected * Voters against proposals to ban pesticides or reduce use * New terrorism laws which could affect 12-year-olds approved By John Revill ZURICH, June 13 (Reuters) - Swiss voters rejected a trio of environmental proposals on Sunday, inclu
B

Swiss voters look set to reject law to help cut carbon emissions

(Repeating to say pix are available, no changes to text) ZURICH, June 13 (Reuters) - Swiss voters look set to reject a new law which would help the country meet its goals under the Paris Agreement on Climate Change, according to early indications by national broadcaster SRF on Sunday. Projections showed 51% of voters had voted against the new CO2 l
B
B

Swiss voters look set to reject law to help cut carbon emissions

ZURICH, June 13 (Reuters) - Swiss voters look set to reject a new law which would help the country meet its goals under the Paris Agreement on Climate Change, according to early indications by national broadcaster SRF on Sunday. Projections showed 51% of voters had voted against the new CO2 law in a nationwide referendum conducted under the country
B
B

Many German firms have no women on boards despite quota, study shows

BERLIN, May 27 (Reuters) - The number of women in German boardrooms is only rising slowly despite legal quotas and many large listed German companies have no women on their management teams, a study showed on Thursday. Of the 66 listed firms subject to a new quota for executive management, including 30 on the DAX blue-chip index, 25 have no women o
A
B
E
I

European shares hit record high on Airbus boost, Bayer hurt by Roundup ruling

* Mining stocks, banks were best performers * Airbus jumps on hiking jet output targets * Food and beverage stocks hurt by Tate & Lyle By Ambar Warrick and Shreyashi Sanyal May 27 (Reuters) - European shares closed at a record high on Thursday boosted by Airbus after the planemaker hiked its jet output targets, while German shares weakened after sh
A
B
H
K
P
T
G
E
F
U

Stinkweed to false flax: oilseeds race to reap biofuel bonanza

By Karl Plume and Rod Nickel ARENZVILLE, Illinois, May 26 (Reuters) - A disparate group met in an Illinois field on a windy spring morning to study a crop some call stinkweed. Botanists, businessmen, farmers and federal lawmakers, they all gathered to peer at the waist-high plant usually considered a pest and uprooted on sight because of its foul o
B



Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

We are using cookies to give you the best experience on our website. Read more or change your cookie settings.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.